Chiasma Inc (NASDAQ:CHMA) Director Roni Mamluk sold 10,000 shares of Chiasma stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $6.35, for a total transaction of $63,500.00. Following the sale, the director now owns 10,000 shares of the company’s stock, valued at approximately $63,500. The sale was disclosed in a document filed with the SEC, which is available through this link.
CHMA traded down $0.46 on Wednesday, reaching $5.87. 398,864 shares of the company traded hands, compared to its average volume of 201,574. Chiasma Inc has a one year low of $1.20 and a one year high of $8.29. The firm has a fifty day moving average price of $7.40. The firm has a market capitalization of $186.48 million, a P/E ratio of -4.59 and a beta of 1.20.
Chiasma (NASDAQ:CHMA) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02). Equities research analysts expect that Chiasma Inc will post -1.14 earnings per share for the current year.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Millennium Management LLC purchased a new position in Chiasma during the 4th quarter valued at about $41,000. Dimensional Fund Advisors LP increased its position in Chiasma by 20.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 97,644 shares of the biotechnology company’s stock valued at $304,000 after purchasing an additional 16,658 shares during the period. Deutsche Bank AG increased its position in Chiasma by 27.8% during the 4th quarter. Deutsche Bank AG now owns 78,198 shares of the biotechnology company’s stock valued at $243,000 after purchasing an additional 16,996 shares during the period. Tibra Equities Europe Ltd purchased a new position in Chiasma during the 1st quarter valued at about $200,000. Finally, New Leaf Venture Partners L.L.C. purchased a new position in Chiasma during the 1st quarter valued at about $2,080,000. Institutional investors own 62.78% of the company’s stock.
Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.
See Also: Return on Investment (ROI)
Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.